Yes, bile acid malabsorption is routinely misdiagnosed as IBS, and the numbers are significant. Research consistently shows that 25 to 30 percent of patients carrying an IBS-D diagnosis actually have BAM when formally tested. That is not a rare overlap. It means that in a gastroenterology clinic seeing 100 IBS-D patients, roughly 25 to 30 of them have a specific, treatable condition that has never been identified. The average time from symptom onset to BAM diagnosis exceeds 5 years, and in many cases the diagnosis is never made at all.
How Common Is This Misdiagnosis?
The prevalence data come primarily from studies using SeHCAT scanning in patients who already had an IBS-D diagnosis. A 2009 systematic review by Wedlake and colleagues analyzed data from multiple centers and found that approximately 26 percent of IBS-D patients had abnormal SeHCAT retention, indicating BAM. A 2015 meta-analysis by Slattery and colleagues confirmed this range, placing the estimate at 25 to 30 percent across studies. These are not small, underpowered studies. The consistency across research groups, countries, and time periods makes this one of the more robust findings in functional gastroenterology. Yet the condition remains dramatically undertested.
Why Does BAM Go Undetected?
Several factors combine to keep BAM hidden behind the IBS label. Understanding them helps explain why a condition affecting millions of people worldwide remains largely invisible in clinical practice.
SeHCAT Is Not Available in the United States
The single biggest barrier to BAM diagnosis globally is the limited availability of SeHCAT testing. SeHCAT is the gold standard diagnostic test, validated across decades of research, with clear cutoff values and high accuracy. But it has never received FDA approval, which means it is unavailable in the United States, the largest healthcare market in the world. Without SeHCAT, US clinicians must rely on serum C4 testing (available but not widely ordered) or therapeutic trials of bile acid sequestrants. Neither alternative is as clean or definitive as SeHCAT. The result is that BAM is rarely part of the diagnostic conversation in American gastroenterology practices.
Low Clinician Awareness
Even in the UK, where SeHCAT is available, BAM testing rates remain lower than the prevalence data would justify. A 2020 survey by Kurien and colleagues found that only 38 percent of gastroenterologists routinely considered BAM when evaluating IBS-D patients. This means that even when the test is sitting in the hospital nuclear medicine department, most clinicians are not ordering it. The reasons include insufficient coverage of BAM in medical training, the historical classification of chronic diarrhea as 'functional' once standard tests are negative, and the lack of guidelines mandating BAM testing in IBS-D workups. The British Society of Gastroenterology updated its guidelines in 2019 to recommend SeHCAT testing in IBS-D, but adoption has been gradual.
IBS Is a Diagnosis of Exclusion That Often Excludes Too Little
IBS is defined by the Rome criteria, which are symptom-based. A patient with chronic abdominal pain and altered bowel habits who meets the criteria and has negative basic testing (bloodwork, celiac screen, sometimes colonoscopy) receives an IBS diagnosis. The problem is that 'negative basic testing' does not include BAM testing in most settings. The exclusion list is too short. Celiac disease, inflammatory bowel disease, and thyroid dysfunction are routinely screened for. BAM, which is more prevalent than celiac disease in IBS-D populations, is not. Until BAM testing becomes part of the standard IBS-D exclusion workup, misdiagnosis will continue at scale.
The Diagnostic Delay: More Than 5 Years on Average
A 2017 study by Bannaga and colleagues at a UK center documented that the average time from symptom onset to BAM diagnosis was over 5 years. Some patients waited more than a decade. During that time, they cycled through dietary restrictions, antispasmodics, antidepressants, and lifestyle modifications, none of which addressed the actual problem. The psychological cost of this delay is substantial. Patients are told they have a 'functional' condition, implying that the issue is in how their gut functions or, in some interpretations, that it is partly psychological. When they finally receive a BAM diagnosis and respond to bile acid sequestrants, the relief is not just physical. It is the validation that comes from having a specific, named condition with a specific treatment.
Post-Cholecystectomy BAM: A Particularly Preventable Delay
Cholecystectomy (gallbladder removal) is one of the most common surgeries performed worldwide, with over 700,000 procedures annually in the United States alone. Between 10 and 20 percent of patients develop chronic diarrhea after surgery. In many cases, this is Type 3 BAM: without the gallbladder to store and regulate bile release, bile flows continuously into the small intestine, and excess bile acids reach the colon. The diagnostic pathway should be straightforward. Patient has gallbladder removed, develops chronic diarrhea within weeks to months, and the obvious next step is BAM testing or a trial of bile acid sequestrants. Yet many of these patients are instead diagnosed with IBS-D and spend years on treatments that do not work. A 2008 systematic review by Fisher and colleagues found that post-cholecystectomy diarrhea is often inadequately investigated, with BAM testing rarely performed despite being the most likely diagnosis.
What Changes When the Diagnosis Is Correct?
The clinical impact of correctly diagnosing BAM is dramatic compared to most conditions that overlap with IBS. Bile acid sequestrants produce symptom improvement in 70 to 80 percent of patients with confirmed BAM. Many patients report substantial improvement within the first week of treatment. Some describe it as transformative after years of uncontrolled diarrhea. This response rate is far higher than any IBS-targeted therapy. Low-FODMAP diet helps about 50 to 70 percent of IBS patients to some degree. Antispasmodics have modest effect sizes. Antidepressants used for IBS have response rates of 40 to 60 percent. A 70 to 80 percent response rate with a specific medication is, in gastroenterology terms, an excellent outcome. It also reinforces the diagnosis: a dramatic response to a bile acid sequestrant in a patient with chronic diarrhea is strong functional evidence of BAM, even without SeHCAT confirmation.
What Should Patients and Clinicians Do Differently?
For patients: if you have IBS-D that has not responded to standard treatments, ask your gastroenterologist directly about bile acid malabsorption. Request a serum C4 level or ask to try a bile acid sequestrant. If you have had your gallbladder removed and developed diarrhea afterward, mention BAM by name. For clinicians: the evidence base supports including BAM in the differential diagnosis for all IBS-D patients. In settings where SeHCAT is available, it should be part of the standard workup. In settings without SeHCAT, a therapeutic trial of colesevelam or cholestyramine is a reasonable and cost-effective diagnostic strategy. The 25 to 30 percent prevalence figure means BAM is not a rare condition requiring specialist suspicion. It is a common condition requiring routine consideration.
If BAM is so common, why have I never heard of it?
BAM has a significant awareness gap. It receives minimal coverage in medical school curricula, the gold standard test is unavailable in the US, and there is no patient advocacy organization driving public awareness the way celiac disease or IBD have. The condition has also suffered from naming confusion: it has been called bile acid diarrhea, bile salt malabsorption, and bile acid malabsorption interchangeably, which dilutes search results and recognition. The research community has been raising alarms about under-diagnosis for over a decade, but clinical practice has been slow to catch up.
Can my primary care doctor test for BAM or do I need a specialist?
In the UK, primary care physicians can order SeHCAT directly in many NHS trusts. In the US, a serum C4 blood test can be ordered by any physician, though not all labs offer it. A therapeutic trial of a bile acid sequestrant can also be initiated by a primary care doctor. However, if your primary care physician is unfamiliar with BAM, a gastroenterologist may be better positioned to order testing and interpret results. Either way, you do not necessarily need a subspecialist referral to begin the diagnostic process.
Is BAM more common in women or men?
Studies show a slight female predominance, but this may reflect the higher rate of IBS-D diagnosis in women rather than a true sex difference in BAM prevalence. Cholecystectomy is also performed more frequently in women, which increases the pool of Type 3 BAM cases. The current evidence does not suggest that sex should change the threshold for testing. Any patient with IBS-D, regardless of sex, has a 25 to 30 percent chance of having BAM.
Could my IBS-D actually be BAM if my colonoscopy was normal?
Absolutely. A normal colonoscopy is expected in BAM. BAM does not cause visible inflammation, ulceration, or structural changes in the colon. It is a biochemical problem, not a structural one. A normal colonoscopy rules out inflammatory bowel disease and microscopic colitis (if biopsies were taken), but it tells you nothing about bile acid metabolism. This is precisely why BAM is missed: the standard exclusion tests used before assigning an IBS diagnosis do not detect it.
What happens if BAM goes untreated for years?
Untreated BAM primarily affects quality of life through persistent diarrhea, urgency, and the social and psychological consequences of living with uncontrolled symptoms. There is some evidence that chronic bile acid exposure in the colon may increase colorectal cancer risk over decades, but this is not firmly established. The more immediate concern is malabsorption of fat-soluble vitamins (A, D, E, K) and essential fatty acids, which can lead to deficiencies over time. The main consequence, however, is years of unnecessary suffering when effective treatment exists.
âšī¸This article is for informational purposes only and does not constitute medical advice. Chronic diarrhea has many potential causes including inflammatory bowel disease, celiac disease, infections, and malignancies. Always consult a qualified healthcare provider for proper diagnosis and treatment.